RHHBY - Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal | Benzinga
HOOKIPA Pharma Inc (NASDAQ:HOOK) will focus its resources on prioritizing the clinical development of a randomized trial for its HB-200 program in human papillomavirus 16 positive (HPV16+) head and neck squamous cell carcinoma (HNSCC) and its two Gilead Science Inc (NASDAQ:GILD)-partnered infectious disease cure programs for hepatitis B and human immunodeficiency virus.
In the first-line setting, the company says HB-200, in combination with Merck & Co Inc (NYSE:MRK) Keytruda (pembrolizumab), has demonstrated antigen-specific T cell activation and has doubled the historic objective ...